Attovia Therapeutics (NASDAQ:ATTO) Stock Gets Price Target Boost from Citigroup

Attovia Therapeutics (NASDAQ:ATTO) had its target price increased by equities research analysts at Citigroup from $30.00 to $34.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price target indicates a potential upside of 108.01% from the company’s current price.

ATTO has been the subject of a number of other reports. Weiss Ratings assumed coverage on Attovia Therapeutics in a research note on Monday, November 2nd. They issued a “sell (e-)” rating for the company. Morgan Stanley increased their target price on Attovia Therapeutics from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday. Lifesci Capital began coverage on Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective for the company. Royal Bank Of Canada initiated coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Wall Street Zen raised shares of Attovia Therapeutics to a “sell” rating in a research note on Saturday, September 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.20.

Attovia Therapeutics Stock Performance

Shares of ATTO stock traded up $0.39 on Tuesday, hitting $16.34. The stock had a trading volume of 82,246 shares, compared to its average volume of 346,537. Attovia Therapeutics has a one year low of $12.94 and a one year high of $28.00. The business has a 50 day moving average price of $18.06. The company has a market capitalization of $746.15 million and a P/E ratio of -3.32.

Attovia Therapeutics (NASDAQ:ATTO) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). The company’s revenue was down 100.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($3.44) EPS. On average, research analysts predict that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year.

About Attovia Therapeutics

Attovia Therapeutics is a clinical-stage biotechnology company developing medicines for inflammatory and immune-mediated diseases. Its research focuses on antibody-based therapies intended to address biological pathways involved in these conditions. The company’s programs are in development, and its work centers on discovering and advancing potential treatments rather than marketing established products. Attovia Therapeutics is listed on the Nasdaq under the symbol ATTO. Publicly available information about the company’s history, leadership and geographic operations is limited.